Rap1 and its regulatory proteins: The tumor suppressor, oncogene, tumor suppressor gene axis in head and neck cancer

Small GTPases

Volumn 3, Issue 3, 2012, Pages 1-7

  Banerjee, Rajat ^a   Russo, Nickole ^a   Liu, Min ^a   van Tubergen, Elizabeth ^a   D'Silva, Nisha J ^a,b  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

EZH2; Methylation; Mir 101; Rap1GAP; Translational

Indexed keywords

DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; HISTONE METHYLTRANSFERASE; MICRORNA 101; NERVE CELL ADHESION MOLECULE; RAP1 PROTEIN; TRANSCRIPTION FACTOR EZH2; UVOMORULIN; VIMENTIN; EZH2 PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; MICRORNA; POLYCOMB REPRESSIVE COMPLEX 2; RAP1GAP PROTEIN, HUMAN;

ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CELL PROLIFERATION; DEACETYLATION; DOWN REGULATION; ENZYME REGULATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; ONCOGENE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METHYLATION; RAP1GAP GENE; SURVIVAL RATE; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; UPREGULATION; ANIMAL; CARCINOMA; GENETICS; HEAD; HEAD AND NECK TUMOR; METABOLISM; NECK; PATHOLOGY; SQUAMOUS CELL CARCINOMA;

ANIMALS; CARCINOMA, SQUAMOUS CELL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GTPASE-ACTIVATING PROTEINS; HEAD AND NECK NEOPLASMS; HUMANS; MICRORNAS; POLYCOMB REPRESSIVE COMPLEX 2; RAP1 GTP-BINDING PROTEINS;

EID: 84863799452     PISSN: 21541248     EISSN: 21541256     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011; 11:9-22; PMID:21160525; http:// dx.doi.org/10.1038/nrc2982.
2. Todd R, Donoff RB, Wong DT. The molecular biology of oral carcinogenesis: toward a tumor progression model. J Oral Maxillofac Surg 1997; 55:613-23; PMID:9191644; http://dx.doi.org/10.1016/S0278-2391(97)90495-X.
3. Bsoul SA, Huber MA, Terezhalmy GT. Squamous cell carcinoma of the oral tissues: a comprehensive review for oral healthcare providers. J Contemp Dent Pract 2005; 6:1-16; PMID:16299602.
4. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011; 333:1154-7; PMID:21798897; http://dx.doi.org/10.1126/science. 1206923.
5. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011; 333:1157-60; PMID:21798893; http://dx.doi.org/10.1126/science.1208130.
6. Kumar B, Cordell KG, Lee JS, Prince ME, Tran HH, Wolf GT, et al. Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender and smoking. Int J Radiat Oncol Biol Phys 2007; 69:109-11; PMID:17848274; http://dx.doi.org/10.1016/j.ijrobp.2007.05.072.
7. Urba S, Wolf G, Eisbruch A, Worden F, Lee J, Bradford C, et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol 2006; 24:593-8; PMID:16380415; http://dx.doi.org/10.1200/ JCO.2005.01.2047.
8. Bauer JA, Kumar B, Cordell KG, Prince ME, Tran HH, Wolf GT, et al. Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 69:106-8; PMID:17848273; http://dx.doi. org/10.1016/j.ijrobp.2007.05.080.
9. Bokoch GM. Biology of the Rap proteins, members of the ras superfamily of GTP-binding proteins. Biochem J 1993; 289:17-24; PMID:8424755.
10. Farrell F, Torti M, Lapetina EG. Rap proteins: investigating their role in cell function. J Lab Clin Med 1992; 120:533-7; PMID:1402329.
11. Barbacid M. ras genes. Annu Rev Biochem 1987; 56:779-827; PMID:3304147; http://dx.doi. org/10.1146/annurev.bi.56.070187.004023.
12. Altschuler DL, Peterson SN, Ostrowski MC, Lapetina EG. Cyclic AMP-dependent activation of Rap1b. J Biol Chem 1995; 270:10373-6; PMID:7737967; http://dx.doi.org/10.1074/jbc.270.18.10373.
13. Frische EW, Zwartkruis FJ. Rap1, a mercenary among the Ras-like GTPases. Dev Biol 2010; 340:1-9; PMID:20060392; http://dx.doi.org/10.1016/j. ydbio.2009.12.043.
14. Banerjee R, Henson BS, Russo N, Tsodikov A, D'Silva NJ. Rap1 mediates galanin receptor 2-induced proliferation and survival in squamous cell carcinoma. Cell Signal 2011; 23:1110-8; PMID:21345369; http:// dx.doi.org/10.1016/j.cellsig.2011.02.002.
15. Henson BS, Neubig RR, Jang I, Ogawa T, Zhang Z, Carey TE, et al. Galanin receptor 1 has antiproliferative effects in oral squamous cell carcinoma. J Biol Chem 2005; 280:22564-71; PMID:15767248; http://dx.doi.org/10.1074/jbc.M414589200.
16. Banerjee R, Mani RS, Russo N, Scanlon CS, Tsodikov A, Jing X, et al. The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. Oncogene 2011; 30:4339-49; PMID:21532618; http://dx.doi.org/10.1038/onc.2011.141.
17. Gloerich M, Bos JL. Regulating Rap small G-proteins in time and space. Trends Cell Biol 2011; 21:615-23; PMID:21820312; http://dx.doi.org/10.1016/j. tcb.2011.07.001.
18. D'Silva NJ, Mitra RS, Zhang Z, Kurnit DM, Babcock CR, Polverini PJ, et al. Rap1, a small GTP-binding protein is upregulated during arrest of proliferation in human keratinocytes. J Cell Physiol 2003; 196:532-40; PMID:12891710; http://dx.doi. org/10.1002/jcp.10331.
19. Mitra RS, Zhang Z, Henson BS, Kurnit DM, Carey TE, D'Silva NJ. Rap1A and rap1B ras-family proteins are prominently expressed in the nucleus of squamous carcinomas: nuclear translocation of GTP-bound active form. Oncogene 2003; 22:6243-56; PMID:13679863; http://dx.doi.org/10.1038/ sj.onc.1206534.
20. Zhang Z, Mitra RS, Henson BS, Datta NS, McCauley LK, Kumar P, et al. Rap1GAP inhibits tumor growth in oropharyngeal squamous cell carcinoma. Am J Pathol 2006; 168:585-96; PMID:16436672; http:// dx.doi.org/10.2353/ajpath.2006.050132.
21. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j. cell.2011.02.013.
22. Mitra RS, Goto M, Lee JS, Maldonado D, Taylor JM, Pan Q, et al. Rap1GAP promotes invasion via induction of matrix metalloproteinase 9 secretion, which is associated with poor survival in low N-stage squamous cell carcinoma. Cancer Res 2008; 68:3959-69; PMID:18483282; http://dx.doi.org/10.1158/0008-5472.CAN-07-2755.
23. Balzac F, Avolio M, Degani S, Kaverina I, Torti M, Silengo L, et al. E-cadherin endocytosis regulates the activity of Rap1: a traffic light GTPase at the crossroads between cadherin and integrin function. J Cell Sci 2005; 118:4765-83; PMID:16219685; http:// dx.doi.org/10.1242/jcs.02584.
24. Hogan C, Serpente N, Cogram P, Hosking CR, Bialucha CU, Feller SM, et al. Rap1 regulates the formation of E-cadherin-based cell-cell contacts. Mol Cell Biol 2004; 24:6690-700; PMID:15254236; ht tp: //dx. doi.org/10.1128/MCB.24.15.6690-700.2004.
25. Knox AL, Brown NH. Rap1 GTPase regulation of adherens junction positioning and cell adhesion. Science 2002; 295:1285-8; PMID:11847339; http:// dx.doi.org/10.1126/science.1067549.
26. Shimizu Y, Hamazaki Y, Hattori M, Doi K, Terada N, Kobayashi T, et al. SPA-1 controls the invasion and metastasis of human prostate cancer. Cancer Sci 2011; 102:828-36; PMID:21251160; http://dx.doi. org/10.1111/j.1349-7006.2011.01876.x.
27. Bailey CL, Kelly P, Casey PJ. Activation of Rap1 promotes prostate cancer metastasis. Cancer Res 2009; 69:4962-8; PMID:19470770; http://dx.doi. org/10.1158/0008-5472.CAN-08-4269.
28. Tsygankova OM, Ma C, Tang W, Korch C, Feldman MD, Lv Y, et al. Downregulation of Rap1GAP in human tumor cells alters cell/matrix and cell/ cell adhesion. Mol Cell Biol 2010; 30:3262-74; PMID:20439492; http://dx.doi.org/10.1128/ MCB.01345-09.
29. Rousseau-Merck MF, Pizon V, Tavitian A, Berger R. Chromosome mapping of the human RAS-related RAP1A, RAP1B and RAP2 genes to chromosomes 1p12-p13, 12q14 and 13q34, respectively. Cytogenet Cell Genet 1990; 53:2-4; PMID:2108841; http:// dx.doi.org/10.1159/000132883.
30. Takai Y, Kaibuchi K, Kikuchi A, Sasaki T, Shirataki H. Regulators of small GTPases. Ciba Found Symp 1993; 176:128-38; PMID:8299416.
31. Wittchen ES, Hartnett ME. The small GTPase Rap1 is a novel regulator of RPE cell barrier function. Invest Ophthalmol Vis Sci 2011; 52:7455-63; PMID:21873678; http://dx.doi.org/10.1167/iovs.11-7295.
32. Goto M, Mitra RS, Liu M, Lee J, Henson BS, Carey T, et al. Rap1 stabilizes beta-catenin and enhances beta-catenin-dependent transcription and invasion in squamous cell carcinoma of the head and neck. Clin Cancer Res 2010; 16:65-76; PMID:20028760; http://dx.doi.org/10.1158/1078-0432.CCR-09-1122.
33. Wang Z, Dillon TJ, Pokala V, Mishra S, Labudda K, Hunter B, et al. Rap1-mediated activation of extracellular signal-regulated kinases by cyclic AMP is dependent on the mode of Rap1 activation. Mol Cell Biol 2006; 26:2130-45; PMID:16507992; http:// dx.doi.org/10.1128/MCB.26.6.2130-45.2006.
34. Herceg Z, Hainaut P. Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. Mol Oncol 2007; 1:26-41; PMID:19383285; http://dx.doi.org/10.1016/j. molonc.2007.01.004.
35. Kondo T, Asa SL, Ezzat S. Epigenetic dysregulation in thyroid neoplasia. [ix.]. Endocrinol Metab Clin North Am 2008; 37:389-400, [ix] PMID:18502333; http://dx.doi.org/10.1016/j.ecl.2007.12.002.
36. McCabe MT, Brandes JC, Vertino PM. Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res 2009; 15:3927-37; PMID:19509173; http://dx.doi.org/10.1158/1078-0432.CCR-08-2784.
37. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008; 27:7274-84; PMID:18806826; http://dx.doi. org/10.1038/onc.2008.333.
38. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419:624-9; PMID:12374981; http://dx.doi.org/10.1038/ nature01075.
39. Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 2011; 71:225-33; PMID:21199804; http://dx.doi.org/10.1158/0008-5472.CAN-10-1850.
40. Kidani K, Osaki M, Tamura T, Yamaga K, Shomori K, Ryoke K, et al. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol 2009; 45:39-46; PMID:18619895; http://dx.doi. org/10.1016/j.oraloncology.2008.03.016.
41. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009; 114:2733-43; PMID:19638619; http:// dx.doi.org/10.1182/blood-2009-03-213496.
42. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, et al. Pharmacologic disruption of Polycombrepressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007; 21:1050-63; PMID:17437993; http://dx.doi. org/10.1101/gad.1524107.
43. Suvà ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 2009; 69:9211-8; PMID:19934320; http://dx.doi. org/10.1158/0008-5472.CAN-09-1622.